Literature DB >> 19092342

Predicting systemic disease in patients with esophageal cancer after esophagectomy: a multinational study on the significance of the number of involved lymph nodes.

Christian G Peyre1, Jeffrey A Hagen, Steven R DeMeester, Jan J B Van Lanschot, Arnulf Hölscher, Simon Law, Alberto Ruol, Ermanno Ancona, S Michael Griffin, Nasser K Altorki, Thomas W Rice, John Wong, Toni Lerut, Tom R DeMeester.   

Abstract

OBJECTIVE: The aim of this study was to determine whether the risk of systemic disease after esophagectomy can be predicted by the number of involved lymph nodes. SUMMARY BACKGROUND DATA: Primary esophagectomy is curative in some but not all patients with esophageal cancer. Identification of patients at high risk for systemic disease would allow selective use of additional systemic therapy. This study is a multinational, retrospective review of patients treated with resection alone to assess the impact of the number of involved lymph nodes on the probability of systemic disease.
METHODS: The study population included 1,053 patients with esophageal cancer (700 adenocarcinoma, 353 squamous carcinoma) who underwent R0 esophagectomy with > or =15 lymph nodes resected at 9 international centers: Asia (1), Europe (5), and United States (3). To ensure a minimum potential follow-up of 5 years, only patients who had esophagectomy before October 2002 were included. Patients treated with neoadjuvant or adjuvant therapy were excluded. The impact of the number of involved lymph nodes on the risk of systemic disease recurrence was assessed using univariate and multivariate analyses.
RESULTS: Systemic disease occurred in 40%. The number of involved lymph nodes ranged from 0 to 26 with 55% of patients having at least 1 involved lymph node. The frequency of systemic disease after esophagectomy was 16% for those without nodal involvement and progressively increased to 93% in patients with 8 or more involved lymph nodes.
CONCLUSIONS: This study shows that the number of involved lymph nodes can be used to predict the likelihood of systemic disease in patients with esophageal cancer. The probability of systemic disease exceeds 50% when 3 or more nodes are involved and approaches 100% when the number of involved nodes is 8 or more. Additional therapy is warranted in these patients with a high probability of systemic disease.

Entities:  

Mesh:

Year:  2008        PMID: 19092342     DOI: 10.1097/SLA.0b013e3181904f3c

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  58 in total

Review 1.  Multi-modality therapy for cancer of the esophagus and GE junction.

Authors:  Mohamedtaki A Tejani; Barbara A Burtness
Journal:  Curr Treat Options Oncol       Date:  2012-09

2.  Prognostic impact of lymph node involvement and the extent of lymphadenectomy (LAD) in adenocarcinoma of the esophagogastric junction (AEG).

Authors:  Leila Sisic; Susanne Blank; Wilko Weichert; Dirk Jäger; Christoph Springfeld; Marcel Hochreiter; Markus Büchler; Katja Ott
Journal:  Langenbecks Arch Surg       Date:  2013-07-26       Impact factor: 3.445

3.  Recurrence risk model for esophageal cancer after radical surgery.

Authors:  Jincheng Lu; Hua Tao; Dan Song; Cheng Chen
Journal:  Chin J Cancer Res       Date:  2013-10       Impact factor: 5.087

Review 4.  Society for Translational Medicine Expert consensus on the selection of surgical approaches in the management of thoracic esophageal carcinoma.

Authors:  Yousheng Mao; Zhentao Yu; Bin You; Wentao Fang; Brian Badgwell; Mark F Berry; DuyKhanh P Ceppa; Chun Chen; Haiquan Chen; Miguel A Cuesta; Xavier Benoit D'Journo; Guy D Eslick; Jianhua Fu; Xiangning Fu; Shugeng Gao; Jianxing He; Jie He; Yunchao Huang; Gening Jiang; Zhongmin Jiang; Jae Y Kim; Danqing Li; Hui Li; Shanqing Li; Deruo Liu; Lunxu Liu; Yongyu Liu; Xiaofei Li; Yin Li; Weimin Mao; Daniela Molena; Christopher R Morse; Nuria M Novoa; Lijie Tan; Qunyou Tan; Alper Toker; Ti Tong; Qun Wang; Benny Weksler; Lin Xu; Shidong Xu; Tiansheng Yan; Lanjun Zhang; Xingyi Zhang; Xun Zhang; Zhu Zhang; Xiuyi Zhi; Qinghua Zhou
Journal:  J Thorac Dis       Date:  2019-01       Impact factor: 2.895

5.  Is the transthoracic approach no longer a viable option for Siewert type II esophagogastric junction carcinoma?

Authors:  Hiroharu Yamashita; Yasuyuki Seto
Journal:  Transl Gastroenterol Hepatol       Date:  2016-03-16

6.  Preoperative lymph node status on computed tomography influences the survival of pT1b, T2 and T3 esophageal squamous cell carcinoma.

Authors:  Kotaro Sugawara; Hiroharu Yamashita; Yukari Uemura; Koichi Yagi; Masato Nishida; Susumu Aikou; Sachiyo Nomura; Yasuyuki Seto
Journal:  Surg Today       Date:  2018-11-23       Impact factor: 2.549

Review 7.  Nutrition therapy issues in esophageal cancer.

Authors:  Keith R Miller; Matthew C Bozeman
Journal:  Curr Gastroenterol Rep       Date:  2012-08

Review 8.  Treatment of esophagogastric junction carcinoma: an unsolved debate.

Authors:  Michele Orditura; Gennaro Galizia; Eva Lieto; Ferdinando De Vita; Fortunato Ciardiello
Journal:  World J Gastroenterol       Date:  2015-04-21       Impact factor: 5.742

9.  High-dose chemoradiotherapy followed by surgery versus surgery alone in esophageal cancer: a retrospective cohort study.

Authors:  Meysan Hurmuzlu; Kjell Øvrebø; Odd R Monge; Rune Smaaland; Tore Wentzel-Larsen; Asgaut Viste
Journal:  World J Surg Oncol       Date:  2010-06-01       Impact factor: 2.754

Review 10.  [Carcinoma of the esophagus, esophagogastric junction, and stomach. Cooperation between pathology and surgery].

Authors:  A H Hölscher; U K Fetzner
Journal:  Pathologe       Date:  2012-11       Impact factor: 1.011

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.